259809-69-3

Basic information

• Product Name: 4-Oxazoleethanol, 2-[(1E)-2-phenylethenyl]-
• Synonyms: 4-(2-hydroxyethyl)-2-(trans-β-styryl)oxazole;4-(2-hydroxyethyl)-2-(trans-styryl)oxazole;2-{2-[(E)-2-phenylethenyl]oxazol-4-yl}-1-ethanol;2-[2-((E)-Styryl)-oxazol-4-yl]-ethanol
• CAS NO: 259809-69-3
• Molecular Formula: C13H13NO2
• Molecular Weight: 215.252
• Mol File: 259809-69-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-Oxazoleethanol, 2-[(1E)-2-phenylethenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Oxazoleethanol, 2-[(1E)-2-phenylethenyl]-(259809-69-3)
• EPA Substance Registry System: 4-Oxazoleethanol, 2-[(1E)-2-phenylethenyl]-(259809-69-3)

Safety Data

• Hazardous Substances Data: 259809-69-3(Hazardous Substances Data)

Upstream product

• 259809-68-2 2-[(E)-2-Phenylethenyl]-4-vinyloxazole 
• 280-64-8 9-bora-bicyclo[3.3.1]nonane 
• 259809-67-1 2-[(E)-2-phenylethenyl]oxazole-4-carbaldehyde 

Downstream Products

• 259809-70-6 2-(2-{2-[(E)-2-Phenylethenyl]oxazol-4-yl}ethyl)-1H-isoindol-1,3(2H)-dione 
• 259809-72-8 5-(tert-butoxycarbonyl)-2-(trans-β-styryl)-4,5,6,7-tetrahydrooxazolo[5,4-c]pyridine 
• 259809-71-7 4-[2-(tert-butoxycarbonylamino)ethyl]-2-(trans-β-styryl)oxazole 
• 259809-74-0 5-(tert-butoxycarbonyl)-2-methoxycarbonyl-4,5,6,7-tetrahydrooxazolo[5,4-c]pyridine 

Relevant articles and documents

Design, synthesis, and biological activity of novel factor Xa inhibitors: Improving metabolic stability by S1 and S4 ligand modification

Serine protease factor xa (fXa) inhibitor 1 showed good ex vivo anti-fXa activity upon oral administration in rats. However, it has been revealed that 1 had low metabolic stability against human liver microsomes. To improve the metabolic stability, we att

NOVEL ETHYLENEDIAMINE DERIVATIVES

A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

ETHYLENEDIAMINE DERIVATIVES

The invention relates a compound represented by the formula (1):Q1-Q2-C(=O)-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 represent H or the like; Q1 represents an aromatic ring, heterocyclic ring or the like; Q2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q3 represents a group or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents -CO- or -SO2-, and a medicine which comprises the compound and is useful for thrombosis and embolism.